Core Viewpoint - The article discusses the escalating conflict between two major companies in the medical beauty industry, Huaxi Biological and Juzhi Biological, highlighting the competitive dynamics and market implications of their rivalry, particularly in the context of collagen products and consumer trust [3][4][19]. Group 1: Company Conflict - The conflict between Huaxi Biological and Juzhi Biological has intensified, with accusations of potential fraud being exchanged publicly [3][4]. - Huaxi Biological's sales and stock prices have declined since 2021, while Juzhi Biological's collagen products have seen significant market success [4][19]. - The public dispute has drawn attention to the market dynamics, with another company, Jinbo Biological, benefiting from the situation by avoiding direct confrontation and achieving substantial stock price increases [4][19]. Group 2: Market Dynamics - The market for recombinant collagen products is projected to grow significantly, with a compound annual growth rate of 44.93%, reaching 585.7 billion yuan by 2025 and 2.1938 trillion yuan by 2030 [28]. - Jinbo Biological reported a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92%, with a gross profit margin of 92.02% [28]. - The competitive landscape is shifting, with new materials and products emerging, potentially threatening the current market positions of Huaxi and Juzhi Biological [36][37]. Group 3: Key Individuals - Yang Xia, the owner of Jinbo Biological, has seen her wealth increase significantly due to the company's stock performance, solidifying her status as a prominent figure in the industry [30][29]. - The article notes the historical context of Huaxi Biological's rise and subsequent decline, contrasting it with the current successes of Juzhi and Jinbo Biological [34][35].

Core Viewpoint - The article discusses the escalating conflict between two major companies in the medical beauty industry, Huaxi Biological and Juzhi Biological, highlighting the competitive dynamics and market implications of their rivalry [3][4]. Group 1: Company Conflict - The conflict between Huaxi Biological and Juzhi Biological has intensified, with accusations of potential fraud being exchanged publicly [3][4]. - Huaxi Biological's sales and stock price have declined since 2021, while Juzhi Biological's "recombinant collagen" products have seen significant growth [4][20]. - The public dispute has led to increased attention on the medical beauty sector, with Juzhi Biological's stock price rising significantly amid the controversy [20][28]. Group 2: Market Dynamics - The market for recombinant collagen products is projected to grow rapidly, with a compound annual growth rate of 44.93%, reaching 585.7 billion yuan by 2025 [28]. - Jinzhi Biological, another key player in the recombinant collagen market, reported a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92% [28]. - The gross profit margin for Jinzhi Biological reached 92.02% in 2024, indicating strong profitability compared to other sectors, including Moutai [28]. Group 3: Industry Competition - The article notes that the medical beauty industry is witnessing a "three-women billionaire" competition, with significant figures like Yang Xia from Jinzhi Biological and Zhao Yan from Huaxi Biological [30][34]. - The emergence of new materials in the medical beauty sector poses a potential threat to the current leaders, as consumer preferences may shift [38]. - The lack of standardized testing methods for recombinant collagen products raises concerns about quality and consumer trust, which could impact market dynamics [37].

Core Viewpoint - The article discusses the rise and challenges faced by Juzhi Biotechnology, highlighting its rapid growth in the beauty industry and the recent controversies surrounding its flagship product, the collagen stick. Group 1: Company Overview - Juzhi Biotechnology, founded by Yan Jianya and Fan Daidi, has become a significant player in the beauty industry, with a market value exceeding 450 billion yuan in May 2023, making them the richest couple in Shaanxi [1][2]. - The company specializes in recombinant collagen products, leveraging advanced biotechnology to create products that mimic human collagen [5][6]. Group 2: Recent Controversies - In May 2023, Juzhi Biotechnology faced backlash from competitors and influencers, particularly regarding the safety and authenticity of its collagen stick product [3][11]. - A beauty influencer claimed that the collagen stick contained only 0.0177% of the advertised recombinant collagen, significantly below the stated minimum of 0.1% [11][14]. - Juzhi Biotechnology responded by asserting that their products met industry standards and were undergoing third-party testing to verify their claims [14][16]. Group 3: Market Impact - Following the controversies, Juzhi Biotechnology's stock price dropped over 8%, reducing its market capitalization from 909 billion HKD to 735 billion HKD within ten days [3][19]. - The company has seen significant sales from its collagen stick, generating over 5.15 billion yuan in revenue since its launch, accounting for 82% of the company's total revenue in 2024 [16][19]. Group 4: Competitive Landscape - The article highlights the competitive tension between Juzhi Biotechnology and other industry players, particularly Huaxi Biological, which criticized Juzhi's marketing tactics and product claims [3][19]. - Both companies have invested heavily in marketing, with Juzhi's marketing expenses exceeding 2 billion yuan in 2024, while Huaxi's were around 24.64 billion yuan [19].

Core Viewpoint - The public relations battle between Huaxi Biological and Juzhi Biological has led to a significant market value loss for Juzhi Biological, amounting to 17.4 billion yuan in just 10 days [4]. Group 1: Public Relations Battle - Huaxi Biological publicly criticized the capital market's behavior of favoring collagen while disparaging hyaluronic acid, directly naming Juzhi Biological and several brokerage firms [3][4]. - Juzhi Biological's market value dropped from 90.9 billion yuan to 73.5 billion yuan within 10 days, a decrease of 17.4 billion yuan [4]. - The negative publicity may impact consumer sentiment and Juzhi Biological's performance during the upcoming 618 promotional event [4]. Group 2: Controversial Testing Methods - The primary controversy revolves around the testing methods used to assess the collagen content in Juzhi Biological's products [5][6]. - A beauty blogger claimed that the actual collagen content in Juzhi Biological's product was only 0.0177%, significantly below the stated standard of ≥0.1% [9]. - Juzhi Biological defended its testing methods, stating that the blogger's approach lacked industry standards and that they were involved in formulating these standards [11]. Group 3: Timeline of Events - On May 17, Huaxi Biological published a critical article targeting Juzhi Biological and brokerage firms [18]. - Juzhi Biological did not respond initially, leading to perceptions of a "pillow fight" in the public relations battle [18]. - The timeline of events suggests a coordinated effort by the blogger to raise questions about Juzhi Biological's products, particularly before the 618 sales event [22][23]. Group 4: Industry Implications - The incident serves as a cautionary tale for other beauty and skincare brands regarding the importance of protecting their core assets, particularly product ingredients and their efficacy [33]. - Companies are urged to establish robust standards and testing methods to safeguard against potential public relations crises [34]. - The need for a credible third-party testing framework is emphasized, as the absence of such standards can lead to consumer distrust and brand damage [30].